Search Results

August 2022 A NanoBRET-Based H 3 R Conformational Biosensor to Study Real-Time H 3 Receptor Pharmacology

April 2022 Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare disorders, today announced that the Company entered into a royalty-based financing with an affiliate of R-Bridge Healthcare Fund (the R-Bridge Financing)."

April 2022 John Streicher talks about his work on terpenes found in cannabis as these may be a novel way to treat pain without the negative side effects "Many people are familiar with cannabis, but John

Join the #GPCR movement by becoming a site member for FREE!

Join us now ➡️ https://www.ecosystem.drgpcr.com/dr-gpcr-summit-2022 #gpcr #drgpcr

🔬Join the #GPCR movement today! ➡️ https://www.ecosystem.drgpcr.com/plans-pricing #gpcr #drgpcr

Boston, MA and Santiago de Compostela, Spain — [June 3rd, 2025]  — Dr. GPCR, the global knowledge hub for G protein-coupled receptor (GPCR) research and education, is proud to welcome Celtarys Research to its partner ecosystem. This collaboration aims to amplify the visibility and adoption of Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics. Celtarys Research develops high-quality, fluorescently labeled ligands and innovative chemical biology tools to support real-time, non-radioactive GPCR assays. These tools enable high-resolution binding studies, kinetic analysis, and live-cell imaging, empowering both academic and industrial scientists to uncover GPCR biology with greater precision and speed. As a Dr. GPCR partner, Celtarys will be featured across multiple touchpoints in the ecosystem, including the Dr. GPCR Newsletter , University Courses , and Podcast , as well as the searchable Dr. GPCR Ecosystem Directory —a centralized hub for tools, training, and technology. “We’re thrilled to partner with Celtarys and introduce their high-performance fluorescent ligands to our global GPCR community,”  said Dr. Yamina Berchiche , Founder and CEO of Dr. GPCR. “These tools can dramatically improve how scientists measure ligand-receptor interactions, visualize binding in live cells, and design better experiments, core to advancing GPCR-targeted discovery.” “Dr. GPCR provides a unique platform to reach scientists at every stage of GPCR research,”  said Wilson Gomes , CEO of Celtarys Research. “This partnership will help accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic breakthroughs.” “We’re excited to support the GPCR community with tools that deliver clarity, sensitivity, and speed,”  added Dr. Maria Majellaro , CSO of Celtarys. “Working with Dr. GPCR allows us to engage with researchers worldwide who are shaping the future of receptor-targeted therapies.” To explore Celtarys Research’s catalog and learn more about their GPCR tools, visit  www.celtarys.com . For access to Dr. GPCR’s global network, educational content, and discovery tools, visit  ecosystem.drgpcr.com . ___________ About Dr. GPCR Dr. GPCR is a nonprofit organization connecting the global GPCR community through training, curated news, expert-led courses, and networking. With over 160 podcast episodes, live and on-demand educational programs, and a dynamic partner ecosystem, Dr. GPCR empowers scientists and companies advancing receptor biology and drug discovery. About Celtarys Research Celtarys Research is a biotech company based in Spain that specializes in the development of optimal chemical tools for drug discovery. Their proprietary chemistry platform enables rapid generation of conjugates, such as labeled ligands, with excellent affinity and pharmacological profiles, designed to advance GPCR-targeted assay development, screening, and live-cell imaging.

Come join us from October 10 to 16 to hear about exciting #GPCR research from amazing speakers.

February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined

January 2022 "OXFORD, England--Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Professor Deane joins Exscientia’s technology leadership team, reporting to Chief Technology Officer,

Build the R in R&D. When Sokhom joined Alkermes, the company had a strong development arm, but a relatively underdeveloped

A.; Bohn, L. M.; Makriyannis, A.; Stevens, R. C.; Liu, Z.-J. R.; Cinar, R.; Coffey, N. J.; Wang, J.; Wu, M.; Katritch, V.; Zhao, S.; Kunos, G.; Bohn, L. D.; Irizarry, L.; Trecki, J.; Schwartz, M.; Gerona, R. R.; Martin, B. R.; Abood, M. E. ; Wiethe, R.; Amato, G.; Maitra, R.

If you’re in GPCR discovery or biotech R&D, this is a masterclass in turning deep science into scalable Eric Trinquet joined Cisbio in the early 2000s, working on what would become HTRF—Homogeneous Time-Resolved For Early-Career Scientists: If you want to work in product R&D, learn this: real innovation happens It reflects decades of foundational R&D—from the fluorescent probes of Cisbio’s early days to the receptor-targeting 👉 Join the Dr.

biosensors reveals distinct conformational signatures of β-arrestin1 and 2 when bound to active PTH1R (P-R* specifically by proximal and distal C-terminal phosphorylation and in the absence of GPCR kinases (GRKs) (R* Here, we show differences between conformational changes that are induced by P-R* or R* receptor states

United States. https://www.genome.gov/ Dixon, R. A., Kobilka, B. K., Strader, D. J., Benovic, J. D., Rands, E., Diehl, R. E., Mumford, R. A., Slater, E. E., Sigal, I. S., Caron, M. G., Lefkowitz, R. J., & Strader, C. D. (1986). Nature, 321(6065), 75–79. https://doi.org/10.1038/321075a0 Fredriksson, R., Lagerström, M.

Traffic (Copenhagen, Denmark), 20(7), 465–478. https://doi.org/10.1111/tra.12649 Ribeiro-Oliveira, R. N., Castro, M., Wang, B., Bouley, R., Potts, J. T., Gardella, T. J., & Vilardaga, J. P. (2009). M., & Lefkowitz, R. J. (2003). Z., Wilderman, A., Katakia, T., McCann, T., Yokouchi, H., Zhang, L., Corriden, R., Liu, D., Feigin, M E., French, R. P., Lowy, A. M., & Murray, F. (2018).

Join us for a deep dive into the world of GPCRs. Save the dates: November 17: Join our final Dr. Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100 Sosei Heptares to Host R& D Day Highlighting its Innovative R&D and Late-Stage Development Progress Parker Moss to Join Exscientia

  👉 Explore Trailers & Join Today Inside Revvity's R&D: How pHSense Was Born The day your data surprises And perhaps that’s the deeper story: Revvity’s R&D team didn’t just invent another tool. . 👉 Go behind the scenes with Revvity’s R&D team ➤ Celtarys Research – Advantages of Fluorescent Ligands Your team’s next good decision may start here 🚀 Join Premium Today & Enjoy ➤ 🎓 Full GPCR University

of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge receipt of the first $15 million tranche from its royalty-based financing agreement with an affiliate of R-Bridge Healthcare Fund (the R-Bridge Financing)."

Premont, R. T. & Gainetdinov, R. R.

.; Stephenson, R. J. D.; Reid, R.; Robinson, L.; Ashley, G. W.; Santi, D. V.

Sugiura, R., Satoh, R., & Takasaki, T. (2021). ERK: a double-edged sword in cancer. M., & Lefkowitz, R. J. (2003).

maintaining the responsiveness of canonical G protein-coupled CKRs that bind to the same ligand(s) (Nibbs, R. instance, CCR2 inhibition leads to inhibition of scavenging and elevated plasma levels of CCL2 (Aiello, R.

Di Roberto, R. B., Chang, B., & Peisajovich, S. G. (2017). Kosar, M., Sarott, R. C., Sykes, D. A., Viray, A. E., Vitale, R.

assays for the functional characterization of (psychedelic) substances at the serotonin receptor 5-HT2A R techniques that have been used the most abundantly for the characterization of (psychedelic) 5-HT2A R

fluorescent analogues for real-time binding studies of orphan GPCR GPR3: Save the dates: November 17: Join Releases First Protein Structures in PDB, Advances Lupus Therapy Research Structure Therapeutics Receives R& D Achievement of the Year Award for GPCR Research Bryan Roth, Natural Products, and the John Daly Legacy

Adapted from Drescher H, Weiskirchen S, Weiskirchen R. Flow Cytometry: A Blessing and a Curse. References Drescher H, Weiskirchen S, Weiskirchen R. Flow Cytometry: A Blessing and a Curse.

.; Allen, R. P. G.; Puri, V.; Singh, R. D.; Hanada, K.; Pagano, R. E.; Miller, L. J. Scientific Reports . (16)      Laasfeld, T.; Ehrminger, R.; Tahk, M.-J.; Veiksina, S.; Kõlvart, K. R.; Min, M.; Kopanchuk, S.; Rinken, A. T.; Schwille, P.; Jungmann, R.

Miranda-Pastoriza D, Bernárdez R, Azuaje J, Prieto-Díaz R, Majellaro M, Tamhankar AV, Koenekoop L, González

R luc: Renilla  luciferase, GFP: Green Fluorescent Protein. Innovation in the pharmaceutical industry: New estimates of R&D costs. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Muneta-Arrate I, Diez-Alarcia R, Horrillo I, Meana JJ. Wan Q, Okashah N, Inoue A, Nehmé R, Carpenter B, Tate CG, et al.